#VisualAbstract Glucagon-Like Peptide-1 Receptor Agonists are Protecting in Type 2 Diabetes Mellitus Patients
Click here to read this article in JAMA Internal Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: GLP-1 receptor agonist
Semaglutide improves symptoms and function in obesity-related heart failure
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer ...
Sodium-glucose cotransporter 2 inhibitor use in patients with type 2 diabetes linked to decreased risk of nephrolithiasis
1. A reduced risk of nephrolithiasis was linked with patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter 2 inhibitor ...
#VisualAbstract: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) prescribed for type 2 diabetes are associated with reduced colorectal cancer (CRC) risk compared to other antidiabetic agents
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as compared to ...
High-dose oral semaglutide effectively glycemic control in patients with type 2 diabetes mellitus
1. HbA1c reduction was dose-dependent in the semaglutide group with the greatest change among patients on semaglutide 50 mg. 2. ...
Oral semaglutide effectively reduces bodyweight in non-diabetic adults with obesity
1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in ...
GLP-1 receptor agonists lower adverse cardiac event risk in veterans with type 2 diabetes
1. In this retrospective cohort study, glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of major adverse ...
